Sanofi +2.5% ) and its partner KaloBios Pharmaceuticals +5% ) say the FDA has granted fast-track designation for the investigation of KB001A, an antibody fragment intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa in mechanically-ventilated patients.
http://seekingalpha.com/currents/post/960031?source=feed
http://seekingalpha.com/currents/post/960031?source=feed
No comments:
Post a Comment